US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.32

-0.1800-0.73%

Post-market: 23.97-0.3500-1.44%19:56 EDT

Volume:25.81K

Turnover:629.58K

Market Cap:56.42M

PE:- -

High:24.66

Open:24.66

Low:24.14

Close:24.50

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.54

T/O Rate:1.11%

Dividend:1.71

Dividend Rate:7.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval

NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review

THOMSON REUTERS

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Wingara Ag sets AGM to approve capital raising tools and board re-elections

Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Relmada Therapeutics Q2 EPS USD -0.11

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

The Race to Come up with the Next Big Sleep Drug

Compass Pathways is Maintained at Overweight by Morgan Stanley

Compass Pathways price target raised to $22 from $17 at B. Riley

RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PSIL/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.32,"timestamp":1789588800000,"preClose":24.5,"halted":0,"volume":25811,"hourTrading":{"tag":"盘后","latestPrice":23.97,"preClose":24.32,"latestTime":"19:56 EDT","volume":1038,"amount":24919.4073,"timestamp":1789603002316,"change":-0.35,"changeRate":-0.014391,"amplitude":0.014391},"delay":0,"changeRate":-0.007346938775510192,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Closed","change":-0.18,"latestTime":"09-16 16:00:00 EDT","open":24.66,"high":24.66,"low":24.14,"amount":629579.3309,"amplitude":0.021224,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":24.5,"sharesOutstanding":1184976,"nav":25.051,"aum":58118072.21,"dividendRate":0.070115,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.06,"preClose":24.5,"latestTime":"08:44 EDT","volume":39,"amount":972.7199820000001,"timestamp":1789562657590,"change":0.56,"changeRate":0.022857,"amplitude":0.039592},"postHourTrading":{"tag":"盘后","latestPrice":23.97,"preClose":24.32,"latestTime":"19:56 EDT","volume":1038,"amount":24919.4073,"timestamp":1789603002316,"change":-0.35,"changeRate":-0.014391,"amplitude":0.014391},"volumeRatio":0.538481,"impliedVol":0.5167,"impliedVolPercentile":0.8645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.538481,"shares":2319976,"dividePrice":1.7052,"high":24.66,"amplitude":0.021224,"preClose":24.5,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.32,"eps":0,"divideRate":0.070115,"volume":25811,"delay":0,"ttmEps":0,"open":24.66,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":25.21,"twentyDayClose":26.2,"sixtyDayClose":21.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657664119","title":"Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657664119","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657664119?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:00","pubTimestamp":1786111242,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Relmada Therapeutics (RLMD), Delcath Systems (DCTH) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-relmada-therapeutics-rlmd-delcath-systems-dcth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-relmada-therapeutics-rlmd-delcath-systems-dcth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DCTH","PSIL","RLMD","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610077","title":"FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610077","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610077?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:21","pubTimestamp":1786101688,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) announced that the FDA has completed first-cycle review of the company’s ANDA for its preservative-free ketamine, with n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-completes-review-of-nrx-pharmaceuticals-preservative-free-ketamine-anda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-completes-review-of-nrx-pharmaceuticals-preservative-free-ketamine-anda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","PSIL","NRXP","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061084","title":"FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061084","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657061084?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100507,"startTime":"0","endTime":"0","summary":"FDA flags packaging certification as sole major deficiency for NRx preservative-free ketamine ANDA approvalFDA completed first-cycle review of NRX Pharmaceuticals’ preservative-free ketamine ANDA with","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL6YBV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FAN.UK","NRXP","BK5026","BK4588","LU0728928796.USD","BK4007","LU0757432629.USD","LU0314104364.USD","SG9999014039.USD","LU1815337578.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU0640478920.SGD","LU0282719219.EUR","IE00BKPKM429.USD","LU2095319765.USD","BK4112","NDAQ","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0757432546.USD","SG9999014021.USD","PSIL","SG9999014005.SGD","BK4585","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU1815337495.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617099","title":"NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617099?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617087","title":"NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617087?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657170556","title":"NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2657170556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657170556?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161707","title":"FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657161707?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699541","title":"These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699541?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:15","pubTimestamp":1786079700,"startTime":"0","endTime":"0","summary":"Biotech stocks have recaptured investors' attention this year amid a wave of drug innovation, which is spurring merger-and-acquisition activity in the biopharma industry and a fresh round of initial p","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXH","LU2596442595.SGD","FHLC","PPH","LU1974910355.USD","BK4578","IYH","PBLS","IE000M9KFDE8.USD","BMED","NVS","PSIL","LU1061106388.HKD","LU1037948541.HKD","MRK","RXL","XBI","PAWZ","LU2125154778.USD","LU1929549753.HKD","XLV","LU0456855351.SGD","BMY","IE00BJJMRZ35.SGD","LU2461242641.AUD","LU0980610538.SGD","LU1023059063.AUD","TRUH","LU1430594728.SGD","HRTS","IHE","LU0061475181.USD","NVIB","LU0320765489.SGD","SG9999001440.SGD","LU0965508806.USD","SG9999014575.USD","LU1934455194.USD","IE00B1BXHZ80.USD","IXJ","GDOC","LU0122379950.USD","LU1941712348.USD","LU2491050154.USD","BBC","VHT","MEDX","LU0306807586.USD","JDOC","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529664","title":"Wingara Ag sets AGM to approve capital raising tools and board re-elections","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:29","pubTimestamp":1786058949,"startTime":"0","endTime":"0","summary":"Wingara Ag Ltd. ( ($AU:WNR) ) has issued an update. Wingara Ag Ltd has called its Annual General Meeting for 7 September 2026 in Melbourne, where s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","AGM","BK4195","BK4229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666177","title":"Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666177","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666177?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:49","pubTimestamp":1786052975,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRelmada Therapeutics IncRLMD.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657931666","title":"Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657931666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657931666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:41","pubTimestamp":1786052519,"startTime":"0","endTime":"0","summary":"Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancerRelmada outlined NDV-01 as its lead program, a sustained-release intravesical gemcitabine/doce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1WTVbn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2324357040.USD","LU2065171311.SGD","LU0320765992.SGD","SBIO","IBRN","LU0154245673.USD","IE00BJT1NW94.SGD","LU2065169927.USD","IE00BJJMRZ35.SGD","IMRX","IE00B2B36J28.USD","BK4563","BK4539","BK4139","IE0002141913.USD","LU2065170008.USD","NBIX","PSIL","LU0889565916.HKD","LU0823416689.USD","IE0009355771.USD","LU0109394709.USD","LU2065171402.SGD","PRAX","XENE","IE00BFTCPJ56.SGD","GHRS","LU0154245756.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657579136","title":"Relmada Therapeutics Q2 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2657579136","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657579136?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:06","pubTimestamp":1786046764,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Q2 EPS USD -0.11Aug 06 (Reuters) - Relmada Therapeutics Q2 net income USD -12.9 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX88ZKJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","RLMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","BK4588","LU0149725797.USD","LU2092937221.SGD","BK4007","IE00BHPRN162.USD","IE00BFXG1179.USD","BK4121","LU0971096721.USD","A","IND","LU2237443622.USD","LU2229751404.USD","LU2237443549.SGD","LU2746668461.USD","LU2237443978.SGD","IE00BKVL7J92.USD","LU1543694498.USD","IE00BN0W2W23.USD","R","PWS","CMC","RLMD","IE00BN0W2T93.GBP","BK4139","IE00B1BXHZ80.USD","LU2237443895.HKD","LU0347712357.USD","BK4006","LU1721428933.USD","PSIL","LU1721429402.USD","IE00BZ1G4Q59.USD","BK4567","EES","BK4505","LENZ","IE00BN0W2V16.EUR","LU2041044095.USD","ALLO","LU2089279066.USD","LU1721429741.USD","LU2237443465.HKD","LU2413666699.HKD","BK4232","LU2413666426.HKD","LU0882574139.USD","BK4585","LU2746668974.SGD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0094547139.USD","LU1548497426.USD","GB00BDT5M118.USD","LU2602419157.SGD","WDNA","LU2089283258.USD","IE00B4JS1V06.HKD","LU0238689110.USD","LU1035775433.USD","LU1868837300.USD","LU0109391861.USD","IE00BFSS8Q28.SGD","IE00B1BXHZ80.USD","LU2324357040.USD","LU2491050071.SGD","LU0683600562.USD","SGXZ51526630.SGD","SG9999014898.SGD","LU0058720904.USD","LU0256863902.USD","LU2112291526.USD","LU2756315664.SGD","LU2211815571.USD","BK4516","LU0640476718.USD","IHE","ELIL","LU2361045086.USD","SG9999015945.SGD","IE00B1XK9C88.USD","LU2750360641.GBP","TMED","LU1623119135.USD","LU2417539215.USD","SG9999015978.USD","IBRN","LU2237443978.SGD","LU0096364046.USD","LU1023059063.AUD","ALKS","IYH","LU1280957306.USD","LU0266013472.USD","SGXZ99366536.SGD","LU2237443895.HKD","LU2237438978.USD","BK4139","IE00BK4W5M84.HKD","IE00B2B36J28.USD","LU0882574139.USD","LU1323610961.USD","LU0354030438.USD","LU2456880835.USD","LU2264538146.SGD","LU2265009873.SGD","LU0689472784.USD","LU2552382215.SGD","LU2168564065.EUR","ILDR","BK4534","LU0109394709.USD","IE00BFSS7M15.SGD","LU0323591593.USD","LU0820562030.AUD","LU0823434583.USD","LU2168564495.EUR","LU1366192091.USD","LLY","LU2237443465.HKD","THNR","LU1291159041.SGD","PPH","LU0133085943.USD","LU0672654240.SGD","LU0079474960.USD","IE0004445015.USD","LU2063271972.USD","LU1069344957.HKD","LU1720051017.SGD","LU0353189763.USD","LU0097036916.USD","AGNG","LU1720051108.HKD","GDOC","SG9999018857.SGD","LU0820561818.USD","LU1232071149.USD","LU1551013342.USD","LU1917777945.USD","LU2087625088.SGD","LU2471134952.CNY","LU0345770993.USD","LU0106261372.USD","VHT","LU1989771016.USD","LU2896262040.SGD","LU1629891620.HKD","LU0964807845.USD","LU1814569148.SGD","LU0158827948.USD","LU2491050154.USD","PJP","RXL","LU2237443549.SGD","LU0432979614.USD","IXJ","TAK","LLYX","LU0225283273.USD","LU0210536198.USD","LU0471298777.SGD","LU1145028129.USD","LU2462591350.SGD","IE0001KFT4U8.USD","MEDI","LU0456855351.SGD","SGXZ81514606.USD","LU2168564149.EUR","LLYZ","LU0006306889.USD","LU2028103732.USD","LU0385154629.USD","LU2552382132.HKD","LU2111349929.HKD","SG9999001176.USD","LU1267930730.SGD","BK4007","LU2361044949.HKD","LU0823434740.USD","LU1057294990.SGD","LU1093756168.USD","LU0354030511.USD","LU2462157665.USD","IE00BKPKM429.USD","LU0471298694.HKD","FBT","PSCH","IE00B7KXQ091.USD","IE00BK4W5L77.USD","LU0466842654.USD","LU1064131342.USD","LU0320765059.SGD","IE00BFTCPJ56.SGD","LU2271345857.HKD","PSIL","LU0820561909.HKD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU0882574055.USD","BK4585","LU1974910355.USD","LU1983299246.USD","LU1093756325.SGD","BK4599","LU1988902786.USD","IE00BN29S564.USD","LU0353189680.USD","IE00BJJMRX11.SGD","JDOC","LU0943347566.SGD","SGXZ31699556.SGD","LU0234572021.USD","MHIP","SG9999001176.SGD","BK4533","HRTS","LU0316494557.USD","BK4588","CURE","IE00B775H168.HKD","IE00BJJMRZ35.SGD","LU1868837136.USD","IE00BWXC8680.SGD","LU2471134523.USD","LU1868836591.USD","IE00BJLML261.HKD","FHLC","IE0002141913.USD","LU1712237335.SGD","LU2023250330.USD","LU0122379950.USD","LU2168564222.USD","CANC","IE00BJJMRY28.SGD","SG9999014880.SGD","LU2089984988.USD","SG9999015986.USD","LU2756315318.SGD","OZEM","LU2237443622.USD","LU2471134879.HKD","LU0417517546.SGD","LU0889565916.HKD","LU2108987350.USD","TRUH","LU2023250504.SGD","LU1061106388.HKD","LU1868836914.USD","LU2236285917.USD","LU2237443382.USD","LU2360106947.USD","BK4581","LU0345770308.USD","IE0005OL40V9.USD","LU0061475181.USD","LU2461242641.AUD","LU0174119429.USD","SG9999017495.SGD","LU2106854487.HKD","SG9999014914.USD","LU2023251221.USD","LU2168563687.JPY","LU1127390331.HKD","LU2491049909.HKD","LU2750360997.AUD","LU2357305700.SGD","SG9999014906.USD","SG9999018865.SGD","SGXZ57979304.SGD","LU0203201768.USD","LU1979441026.SGD","LU0158827781.USD","LU2471134796.USD","LU1804176565.USD","IE00B4R5TH58.HKD","IE00BKDWB100.SGD","LU2468319806.SGD","LU0198837287.USD","LU0203202063.USD","FTXH","LU2089284900.SGD","SG9999015952.SGD","LLII","SG9999013999.USD","LU0786609619.USD","LU2361044865.SGD","LU1551013425.SGD","LU0787776722.HKD","LU0823416689.USD","IE0004445239.USD","LU2746668461.USD","XLV","LU1868836757.USD","LU0256863811.USD","LU0708995401.HKD","LU2552382058.USD","LU2213496289.HKD","ELIS","LU2746668974.SGD","MEDX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651829","title":"Compass Pathways is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651829","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651829?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:55","pubTimestamp":1786038900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637864","title":"Compass Pathways price target raised to $22 from $17 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637864?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:38","pubTimestamp":1786023496,"startTime":"0","endTime":"0","summary":"B. Riley analyst Madison El-Saadi raised the firm’s price target on Compass Pathways (CMPS) to $22 from $17 and keeps a Buy rating on the shares po...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631659","title":"RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631659?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:32","pubTimestamp":1786019564,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $23.35, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","VNDA","BK4007","IE0009355771.USD","PRAX","IE00BJT1NW94.SGD","BK4139","IE00BFTCPJ56.SGD","PSIL","BK4539","HRMY","LU0109394709.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IBRN","GHRS","LU0320765992.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663689","title":"Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663689","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663689?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:58","pubTimestamp":1786017486,"startTime":"0","endTime":"0","summary":"Ireland's GH Research Q2 net loss widens on higher R&D costsOverviewIreland biopharmaceutical firm's Q2 net loss widened yr/yr, with higher R&D and G&A expensesCompany's cash and marketable securities","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4007","LU0823416689.USD","LU0889565916.HKD","BK4539","CNTX","LU0154245673.USD","BK4139","LU0154245756.USD","IE00BN0W2V16.EUR","JAZZ","CMPS","LU0320765992.SGD","PSIL","BK4533","LU0109394709.USD","BK4532","GHRS","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}